Advertisement

Topics

Syngenix Limited Company Profile

02:50 EST 16th December 2018 | BioPortfolio

SynGenix Limited SynGenix has developed technologies that effectively target drugs and drug discovery tools to the anatomical and cellular sites of origin of disease processes. SynGenix can delivery probes such as antisense in vivo for > drug target validation and systems for targeting small drugs and macromolecules to the site of disease. The core platform technologies have been demonstrated by the intracellular delivery of drugs to treat chronic pain and the delivery of antisense to block HIV. SynGenix now intends to take technology to treat chronic and acute pain into man over the coming 24 months and to develop related technologies to target therapeutic and probe molecules to address other unmet disease needs.

Location

Babraham Hall Babraham
Cambridge
Cambridgeshire
CB2 4AT
United Kingdom

Contact

Phone: +44 1223 496090
Fax: +44 1223 496018


News Articles [32 Associated News Articles listed on BioPortfolio]

Quotient Limited Announces Details of Investor Day

JERSEY, Channel Islands, July 16, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced details of its investor day held at the NASDAQ he...

Quotient Limited to Host Investor Day on July 16, 2018

JERSEY, Channel Islands, June 18, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that it will host an Investor Day on Monday, July ...

Quotient Limited Announces Initial MosaiQ™ SDS Verification and Validation Data

JERSEY, Channel Islands, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported positive Verification and Validation...

Quotient Limited Announces Completion of Senior Secured Notes Offering

JERSEY, Channel Islands, July 02, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), has completed the offering of up to $120.0 million ...

Quotient Limited to Participate in the Jefferies 2018 London Healthcare Conference

JERSEY, Channel Islands, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Quotient (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chief Financial Officer, Chris Lindop,...

Quotient Limited Announces Pricing of Underwritten Offering of Ordinary Shares

JERSEY, Channel Islands, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the pricing of its previously annou...

Quotient Limited Announces Proposed Underwritten Offering of Ordinary Shares

JERSEY, Channel Islands, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the Company intends to commence an ...

Quotient Limited to Participate in the 2018 Cantor Fitzgerald Global Healthcare Conference

JERSEY, Channel Islands, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Quotient (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, ...

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [86 Associated Companies listed on BioPortfolio]

Syngenix Limited

SynGenix Limited SynGenix has developed technologies that effectively target drugs and drug discovery tools to the anatomical and cellular sites of origin of disease processes. SynGenix can delivery ...

Microsulis Medical Limited

Founded in 1997, Microsulis Medical Limited is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic d...

Immunocore Limited

Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located ...

SIEMENS CANADA LIMITED

VASUDHA PHARMA CHEM LIMITED

VASUDHA PHARMA CHEM LIMITED (VPCL) is a Company promoted by a team of accomplished technocrats for Bulk Drug industry with a total capital of Rupees 153 million ( US $ 5Million).All the promoters of V...

More Information about "Syngenix Limited" on BioPortfolio

We have published hundreds of Syngenix Limited news stories on BioPortfolio along with dozens of Syngenix Limited Clinical Trials and PubMed Articles about Syngenix Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Syngenix Limited Companies in our database. You can also find out about relevant Syngenix Limited Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Antisense therapy
Most human diseases are caused by production of abnormal proteins or malfunctioning proteins.   Antisense therapy involves inhibiting production of these proteins.  When a gene is known to cause a specific disease and the genetic sequence ...


Corporate Database Quicklinks



Searches Linking to this Company Record